Table 2 Baseline clinical outcome measures
Baseline Outcome Measures | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Clinical outcome measure | All participants (n = 24) | Intervention group (n = 12) | Control group (n = 12) | ||||||
| Â | Mean (SD) | Median (IQR)* | 95% CI | Mean (SD) | Median (IQR)* | 95% CI | Mean (SD) | Median (IQR)* | 95% CI |
HADS Anxiety | 5.88 (5.53) | 4 (6.5) | 3.54–8.21 | 3.42 (3.32) |  | 1.31–5.52 | 8.33 (6.31) | 5.50 (12) | 4.32–12.35 |
HADS Depression | 5.05 (5.68) | 3 (7.75) | 2.64–7.44 | 2.75 (2.86) |  | .93–4.57 | 7.33 (6.92) |  | 2.94–11.73 |
KDQOL Symptom list | 70.76 (22.09) |  | 61.43–80.08 | 78.82 (21.28) |  | 65.30–92.34 | 62.69 (20.63) |  | 49.58–75.80 |
KDQOL Effects of kidney disease | 66.19 (28.60) | 72.5 (50.78) | 54.12–78.27 | 76.29 (22.51) |  | 61.99–90.59 | 56.10 (31.32) |  | 36.19–75-99 |
KDQOL Burden of kidney disease | 33.85 (29.37) | 31.25 (35.94) | 21.45–46.26 | 43.23 (29.85) | 34.38 (34.38) | 24.26–62.20 | 24.48 (26.84) | 18.95 (29.69) | 7.42–41.53 |
KDQOL Physical composite | 29.99 (11.49) | 27.38 (13.16) | 25.14–34.84 | 34.31 (13.33) | 30.46 (25.33) | 25.76–42.70 | 25.75 (7.70) |  | 20.86–30.64 |
KDQOL Mental composite | 49 (13. 70) | 51.52 (17.32) | 43.22–54.78 | 55.03 (6.98) |  | 50.60–59.47 | 42.97 (16.25) |  | 32.64–53.30 |
EQ-5D-5L VAS | 49.71 (24.29) |  | 39.45–59.96 | 57.92 (23.76) |  | 42.82–73.01 | 41.50 (22.84) |  | 26.99–56.01 |